- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
New melanoma device moves ahead
Verisante Technology, a medical device company, has entered into an exclusive licensing agreement with the British Columbia Cancer Agency to manufacture the Verisante Aura, a spectroscopy system designed to aid in the early detection of skin cancer.
Vancouver, British Columbia - Verisante Technology, a medical device company based here, has entered into an exclusive licensing agreement with the British Columbia Cancer Agency to manufacture the Verisante Aura, a spectroscopy system designed to aid in the early detection of skin cancer.
According to a company statement, Verisante officials expect Health Canada approval this year and anticipate that the device will be made available in Canada afterward. Company officials also expect to begin seeking regulatory approval for use and distribution in the United States.
The Verisante Aura technology is based on the Raman spectroscopy method. According to the company, the device has been under development and undergoing testing at the British Columbia Cancer Agency for more than a decade. It has been tested on about 1,000 lesions. Published preliminary clinical findings show that the device caught all 34 cases of melanoma among the first 274 lesions scanned, with results later confirmed by biopsy.
